Our data thus provides a new platform for a co-delivery system with high affinity to liver tumors and further approved the therapeutic effects of combinational therapy with a SIRT7 inhibitor and sorafenib, which offers a new therapeutic option in treatment of human liver cancer. Here, SIRT7 is linked to liver cancer.